Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Pancreatic Neoplasms 295Carcinoma, Non-Small-Cell Lung 160Lung Neoplasms 89Breast Neoplasms 84Urinary Bladder Neoplasms 83Cholangiocarcinoma 58Neoplasms 53Neoplasm Metastasis 51Ovarian Neoplasms 45Biliary Tract Neoplasms 45Lymphoma, Large B-Cell, Diffuse 32Lymphoma 30Sarcoma 29Hodgkin Disease 28Recurrence 26Nasopharyngeal Carcinoma 26Gallbladder Neoplasms 26Carcinoma, Transitional Cell 26Adenocarcinoma 22Triple Negative Breast Neoplasms 20Fallopian Tube Neoplasms 20Bile Duct Neoplasms 20Adenocarcinoma of Lung 20Carcinoma, Renal Cell 17Carcinoma, Ovarian Epithelial 16Urethral Neoplasms 15Lymphoma, Non-Hodgkin 15Colorectal Neoplasms 14Leiomyosarcoma 13Kidney Neoplasms 13

Interventions

Docetaxel 2bleomycin A6 1apatorsen 1Pemetrexed 1Injections 1Gemcitabine 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Squamous Cell Lung Cancer × Gemcitabine × Clear all
NCT02423590 2017-08-22

Study of Gemcitabine/Carboplatin First-line Chemotherapy +/- Apatorsen in Advanced Squamous Cell Lung Cancers

Queen Mary University of London

Phase 2 Unknown
140 enrolled
Thoracic

Squamous Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡